Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Hematologic Oncology Update
00:00
When to consider triple‑drug frontline regimens
She supports triple combinations in selected younger or fit patients, weighing infection risk and anti‑CD20 benefit by IGHV.
Play episode from 24:06
Transcript
